BioPharmSignal logoBioPharmSignal

Biotech News

Innoviva Reports Third Quarter 2026 Financial Results; Highlights Recent Company Progress

Innoviva (INVA)InnovivaEarnings

Innoviva Specialty Therapeutics commercial momentum continues with $43.3 million generated in U.S. net product sales, representing 45% year-over-year growth $58.1 million in quarterly revenue from durable royalty portfolio Returned capital to shareholders through repurchase of 1.2 million shares in

Related news

INVAInnoviva2026-08-05 20:05 EST

Innoviva Reports Second Quarter 2026 Financial Results; Highlights Recent Company Progress

INVAInnoviva2026-05-06 20:05 EST

Innoviva Reports First Quarter 2026 Financial Results; Highlights Recent Company Progress

PMVPPMV Pharmaceuticals2026-08-14 12:00 EST

PMV Pharmaceuticals Reports Second Quarter 2026 Financial Results and Corporate Highlights

PMVPPMV Pharmaceuticals2026-05-12 12:00 EST

PMV Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Highlights

BCRXBioCryst Pharmaceuticals2026-11-04 12:00 EST

BioCryst Reports Third Quarter 2026 Financial Results

EXELExelixis2026-10-29 20:05 EST

Exelixis Announces Third Quarter 2026 Financial Results and Provides Corporate Update

ZNTLZentalis2026-05-12 20:05 EST

Zentalis Pharmaceuticals Reports First Quarter 2026 Financial Results and Clinical Progress

EXELExelixis2026-08-05 20:05 EST

Exelixis Announces Second Quarter 2026 Financial Results and Provides Corporate Update

BCRXBioCryst Pharmaceuticals2026-08-05 11:00 EST

BioCryst Reports Second Quarter 2026 Financial Results

CRISCuris Inc2026-11-05 21:38 EST

Curis to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on November 12, 2026

View all latest news

Innoviva

Diversified Biopharmaceutical Model Innoviva combines a respiratory-royalty portfolio, a commercial critical-care and infectious-disease business, and strategic investments in healthcare companies. Respiratory Royalties The company receives royalties from respiratory medicines partnered with GSK, providing cash flows that support...

Recent company news

INVAInnoviva2026-11-04 21:05 EST

Innoviva Reports Third Quarter 2026 Financial Results; Highlights Recent Company Progress

INVAInnoviva2026-10-19 12:00 EST

Innoviva Specialty Therapeutics to Present Data Across Infectious Disease Portfolio at IDWeek 2026

INVAInnoviva2026-09-02 12:00 EST

Innoviva to Participate in Upcoming Investor Conferences

INVAInnoviva2026-08-11 20:05 EST

Innoviva Specialty Therapeutics’ Antimicrobial Therapies, XACDURO®, ZEVTERA® and NUZOLVENCE® Designated Finalists for the 2026 Prix Galien USA Best Pharmaceutical Product Award

INVAInnoviva2026-08-05 20:05 EST

Innoviva Reports Second Quarter 2026 Financial Results; Highlights Recent Company Progress

Stock data

Close
19.24 USD
Market cap
1.58B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States